Cargando…
Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial
BACKGROUND: Platelet Rich Plasma (PRP), a blood-derived product rich in growth factors, is a promising treatment for cartilage defects but there is still a lack of clinical evidence. The aim of this study is to show, through a randomized double blind prospective trial, the efficacy of this procedure...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532098/ https://www.ncbi.nlm.nih.gov/pubmed/23176112 http://dx.doi.org/10.1186/1471-2474-13-229 |
_version_ | 1782254248278360064 |
---|---|
author | Filardo, Giuseppe Kon, Elizaveta Di Martino, Alessandro Di Matteo, Berardo Merli, Maria Letizia Cenacchi, Annarita Fornasari, Pier Maria Marcacci, Maurilio |
author_facet | Filardo, Giuseppe Kon, Elizaveta Di Martino, Alessandro Di Matteo, Berardo Merli, Maria Letizia Cenacchi, Annarita Fornasari, Pier Maria Marcacci, Maurilio |
author_sort | Filardo, Giuseppe |
collection | PubMed |
description | BACKGROUND: Platelet Rich Plasma (PRP), a blood-derived product rich in growth factors, is a promising treatment for cartilage defects but there is still a lack of clinical evidence. The aim of this study is to show, through a randomized double blind prospective trial, the efficacy of this procedure, by comparing PRP to Hyaluronic Acid (HA) injections for the treatment of knee chondropathy or osteoarthritis (OA). METHODS: 109 patients (55 treated with HA and 54 with PRP) were treated and evaluated at 12 months of follow-up. The patients were enrolled according to the following inclusion criteria: age> 18 years, history of chronic (at least 4 months) pain or swelling of the knee and imaging findings of degenerative changes of the joint (Kellgren-Lawrence Score up to 3). A cycle of 3 weekly injections was administered blindly. All patients were prospectively evaluated before and at 2, 6, and 12 months after the treatment by: IKDC, EQ-VAS, TEGNER, and KOOS scores. Range of motion and knee circumference changes were measured over time. Adverse events and patient satisfaction were also recorded. RESULTS: Only minor adverse events were detected in some patients, such as mild pain and effusion after the injections, in particular in the PRP group, where a significantly higher post-injective pain reaction was observed (p=0.039). At the follow-up evaluations, both groups presented a clinical improvement but the comparison between the two groups showed a not statistically significant difference in all scores evaluated. A trend favorable for the PRP group was only found in patients with low grade articular degeneration (Kellgren-Lawrence score up to 2). CONCLUSIONS: Results suggest that PRP injections offer a significant clinical improvement up to one year of follow-up. However, conversely to what was shown by the current literature, for middle-aged patients with moderate signs of OA, PRP results were not better than those obtained with HA injections, and thus it should not be considered as first line treatment. More promising results are shown for its use in low grade degeneration, but they still have to be confirmed. |
format | Online Article Text |
id | pubmed-3532098 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35320982013-01-03 Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial Filardo, Giuseppe Kon, Elizaveta Di Martino, Alessandro Di Matteo, Berardo Merli, Maria Letizia Cenacchi, Annarita Fornasari, Pier Maria Marcacci, Maurilio BMC Musculoskelet Disord Research Article BACKGROUND: Platelet Rich Plasma (PRP), a blood-derived product rich in growth factors, is a promising treatment for cartilage defects but there is still a lack of clinical evidence. The aim of this study is to show, through a randomized double blind prospective trial, the efficacy of this procedure, by comparing PRP to Hyaluronic Acid (HA) injections for the treatment of knee chondropathy or osteoarthritis (OA). METHODS: 109 patients (55 treated with HA and 54 with PRP) were treated and evaluated at 12 months of follow-up. The patients were enrolled according to the following inclusion criteria: age> 18 years, history of chronic (at least 4 months) pain or swelling of the knee and imaging findings of degenerative changes of the joint (Kellgren-Lawrence Score up to 3). A cycle of 3 weekly injections was administered blindly. All patients were prospectively evaluated before and at 2, 6, and 12 months after the treatment by: IKDC, EQ-VAS, TEGNER, and KOOS scores. Range of motion and knee circumference changes were measured over time. Adverse events and patient satisfaction were also recorded. RESULTS: Only minor adverse events were detected in some patients, such as mild pain and effusion after the injections, in particular in the PRP group, where a significantly higher post-injective pain reaction was observed (p=0.039). At the follow-up evaluations, both groups presented a clinical improvement but the comparison between the two groups showed a not statistically significant difference in all scores evaluated. A trend favorable for the PRP group was only found in patients with low grade articular degeneration (Kellgren-Lawrence score up to 2). CONCLUSIONS: Results suggest that PRP injections offer a significant clinical improvement up to one year of follow-up. However, conversely to what was shown by the current literature, for middle-aged patients with moderate signs of OA, PRP results were not better than those obtained with HA injections, and thus it should not be considered as first line treatment. More promising results are shown for its use in low grade degeneration, but they still have to be confirmed. BioMed Central 2012-11-23 /pmc/articles/PMC3532098/ /pubmed/23176112 http://dx.doi.org/10.1186/1471-2474-13-229 Text en Copyright ©2012 Filardo et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Filardo, Giuseppe Kon, Elizaveta Di Martino, Alessandro Di Matteo, Berardo Merli, Maria Letizia Cenacchi, Annarita Fornasari, Pier Maria Marcacci, Maurilio Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial |
title | Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial |
title_full | Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial |
title_fullStr | Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial |
title_full_unstemmed | Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial |
title_short | Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial |
title_sort | platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532098/ https://www.ncbi.nlm.nih.gov/pubmed/23176112 http://dx.doi.org/10.1186/1471-2474-13-229 |
work_keys_str_mv | AT filardogiuseppe plateletrichplasmavshyaluronicacidtotreatkneedegenerativepathologystudydesignandpreliminaryresultsofarandomizedcontrolledtrial AT konelizaveta plateletrichplasmavshyaluronicacidtotreatkneedegenerativepathologystudydesignandpreliminaryresultsofarandomizedcontrolledtrial AT dimartinoalessandro plateletrichplasmavshyaluronicacidtotreatkneedegenerativepathologystudydesignandpreliminaryresultsofarandomizedcontrolledtrial AT dimatteoberardo plateletrichplasmavshyaluronicacidtotreatkneedegenerativepathologystudydesignandpreliminaryresultsofarandomizedcontrolledtrial AT merlimarialetizia plateletrichplasmavshyaluronicacidtotreatkneedegenerativepathologystudydesignandpreliminaryresultsofarandomizedcontrolledtrial AT cenacchiannarita plateletrichplasmavshyaluronicacidtotreatkneedegenerativepathologystudydesignandpreliminaryresultsofarandomizedcontrolledtrial AT fornasaripiermaria plateletrichplasmavshyaluronicacidtotreatkneedegenerativepathologystudydesignandpreliminaryresultsofarandomizedcontrolledtrial AT marcaccimaurilio plateletrichplasmavshyaluronicacidtotreatkneedegenerativepathologystudydesignandpreliminaryresultsofarandomizedcontrolledtrial |